/LFWD
LFWD Stock - Lifeward Ltd.
Healthcare|Medical - DevicesNASDAQ
$0.63+1.19%
+$0.01 (+1.19%) • Jan 12
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.25
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1608.0%upside
Target: $10.75
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LFWD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.62 – $0.64
TARGET (TP)$10.75
STOP LOSS$0.58
RISK/REWARD1:204.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.00
52W High$2.95
52W Low$0.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $25.66M | $13.85M | $5.51M | $5.97M | $4.39M |
| Gross Profit | $8.22M | $4.45M | $1.91M | $2.90M | $2.19M |
| Gross Margin | 32.0% | 32.1% | 34.6% | 48.7% | 49.8% |
| Operating Income | $-19,553,000 | $-23,612,000 | $-19,102,000 | $-12,655,000 | $-12,004,000 |
| Net Income | $-28,942,000 | $-22,133,000 | $-19,569,000 | $-12,736,000 | $-12,976,000 |
| Net Margin | -112.8% | -159.8% | -355.1% | -213.5% | -295.4% |
| EPS | $-3.33 | $-2.59 | $-2.20 | $-1.86 | $-5.74 |
Company Overview
Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1488.8% Upside
Now
$10
Low
$10
Average
$10
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 10th 2025 | Laidlaw | Initiation | Buy | $10 |
Earnings History & Surprises
LFWDBeat Rate
20%
Last 15 quarters
Avg Surprise
-38.5%
EPS vs Estimate
Beats / Misses
3/12
Last 12 quarters
Latest EPS
$-0.20
Q4 2025
EPS Surprise History
Q1 24
+61.5%
$-0.35vs$-0.91
Q2 24
-4.3%
$-0.73vs$-0.70
Q3 24
+5.7%
$-0.50vs$-0.53
Q4 24
-66.7%
$-0.45vs$-0.27
Q1 25
-90.0%
$-0.38vs$-0.20
Q2 25
-39.4%
$-0.46vs$-0.33
Q3 25
-132.0%
$-0.58vs$-0.25
Q4 25
-122.2%
$-0.20vs$-0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 6, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.09 | $-0.20 | -122.2% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.25 | $-0.58 | -132.0% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.33 | $-0.46 | -39.4% | ✗ MISS |
Q1 2025 | Mar 7, 2025 | $-0.20 | $-0.38 | -90.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.27 | $-0.45 | -66.7% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.70 | $-0.73 | -4.3% | ✗ MISS |
Q1 2024 | Feb 27, 2024 | $-0.91 | $-0.35 | +61.5% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.11 | $-0.13 | -18.2% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $-0.49 | $-0.55 | -11.4% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-0.56 | $-0.51 | +9.2% | ✓ BEAT |
Q4 2022 | Dec 30, 2022 | $-0.49 | $-0.60 | -23.1% | ✗ MISS |
Q3 2022 | Sep 29, 2022 | $-0.42 | $-0.61 | -44.9% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-0.28 | $-0.50 | -77.7% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | — | $-0.49 | — | — |
Q4 2021 | Dec 30, 2021 | $-0.35 | $-0.43 | -23.5% | ✗ MISS |
Q3 2021 | Sep 29, 2021 | — | $-0.40 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.48 | — | — |
Latest News
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Jan 13, 2026, 01:25 PM
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Jan 13, 2026, 12:55 PM
Lifeward Appoints Bob Marshall Board Chairman, Effective Jan. 1, Succeeding Joseph Turk
➖ NeutralBenzinga•Dec 19, 2025, 09:06 PM
Lifeward Expands Patient Access To ReWalk Personal Exoskeleton Through New International Distribution Agreement With Verita Neuro
📈 PositiveBenzinga•Dec 17, 2025, 01:13 PM
HC Wainwright & Co. Maintains Buy on Lifeward, Lowers Price Target to $4.5
➖ NeutralBenzinga•Nov 18, 2025, 11:20 AM
Lifeward Gets First Prior Authorization From UnitedHealthcare Medicare Advantage Plan For ReWalk 7 Personal Exoskeleton
📈 PositiveBenzinga•Nov 17, 2025, 01:05 PM•Also:
Lifeward Affirms FY2025 Sales Guidance of $24.000M-$26.000M vs $25.101M Est
➖ NeutralBenzinga•Nov 14, 2025, 01:02 PM
Lifeward Q3 Adj. EPS $(0.19) Beats $(0.21) Estimate, Sales $6.195M Miss $6.311M Estimate
➖ NeutralBenzinga•Nov 14, 2025, 01:01 PM
Lifeward Receives First Payment From Commercial Medicare Advantage Plan For ReWalk 7 Personal Exoskeleton.
📈 PositiveBenzinga•Sep 9, 2025, 12:32 PM
Lifeward Receives CE Mark For ReWalk 7 Exoskeleton; Expands Commercial Sales In Europe
📈 PositiveBenzinga•Sep 8, 2025, 12:34 PM
The US Defense Health Agency Is Awarding A Sole Source Contract To Lifeward For Surgical And Medical Instrument Manufacturing
📈 PositiveBenzinga•Aug 21, 2025, 02:19 PM
Lifeward stock plummets on pricing of $2.6M public offering
📉 NegativeSeeking Alpha•Jun 25, 2025, 01:17 PM
Frequently Asked Questions about LFWD
What is LFWD's current stock price?
Lifeward Ltd. (LFWD) is currently trading at $0.63 per share. The stock has moved +1.19% today.
What is the analyst price target for LFWD?
The average analyst price target for LFWD is $10.75, based on 1 analyst.
What sector is Lifeward Ltd. in?
Lifeward Ltd. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is LFWD's market cap?
Lifeward Ltd. has a market capitalization of $0.01 billion, making it a small-cap company.
Does LFWD pay dividends?
No, Lifeward Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorDHAI
DIH Holding US, Inc.
$0.00
Mkt Cap: $0.0B
IINN
Inspira Technologies Oxy B.H.N. Ltd.
$0.96
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$2.18
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$2.06
Mkt Cap: $0.0B
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
$0.45
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.95
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.27
Mkt Cap: $0.0B
SINT
Sintx Technologies, Inc.
$3.83
Mkt Cap: $0.0B
TNON
Tenon Medical, Inc.
$0.95
Mkt Cap: $0.0B
XAIR
Beyond Air, Inc.
$0.88
Mkt Cap: $0.0B
Explore stocks similar to LFWD for comparison